November 1, 2017 / 11:56 AM / 2 months ago

BRIEF-IntelGenx and Redhill Biopharma resubmit Rizaport NDA to FDA

Nov 1 (Reuters) - IntelGenx Technologies Corp

* Intelgenx and Redhill Biopharma resubmit Rizaport new drug application to the FDA

* Intelgenx Technologies Corp- ‍co, Redhill Biopharma have resubmitted new drug application to U.S. FDA for Rizaport 10 mg​

* Intelgenx-‍if Rizaport NDA resubmission is complete & permitted a full review by FDA, PDUFA date is expected to be set by agency for first half of 2018​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below